We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
This page is for sponsors and potential sponsors and navigates you through the stages of preparing and submitting an application for inclusion of a Class 2, 3 or 4 biological in the Australian Register of Therapeutic Goods (ARTG).
If you are new to supplying a therapeutic good, you may find our overview of applying for market authorisation helpful.
For new Class 2, 3 and 4 biologicals
This application process is specific to inclusion of new biologicals on the ARTG that are:
- new biological entities classified as Class 2, 3 or 4 biologicals
- a new biological based on a parent biological already on the ARTG.
For inclusion of a new Class 2, 3 or 4 biological via expedited priority pathway; you need to go to Priority inclusion process: Guidance for sponsors of biologicals with (priority applicant) determination
This is not the correct process if you want to apply:
- to vary a biological already included on the ARTG, you may need: Varying biological entries on the ARTG
- for inclusion of a Class 1 biological; you need go to Applying for inclusion of a Class 1 biological on the ARTG
- make a change to a biological (parent biological) already on the ARTG where the change creates a separate and distinct good (new biological), you need to go to new biological based on a parent biological.
Before you apply
There is a considerable amount of information you need to collate before you will be able to apply for inclusion of a biological in the ARTG.
To assist you in preparing for your application, we suggest reading:
Overview of the application process and timeframes
The overall time to evaluate a dossier can vary depending on:
- the quality and complexity of the dossier
- issues raised during the evaluation process and timely response from sponsor
- consideration by the Advisory Committee on Biologicals, if required.
The following Table highlights the standard process for acceptance and review of an application to include a new biological in the ARTG.
Phase | Stage | Description | Target timeframes* | Legislated timeframe* |
---|---|---|---|---|
1 | Pre-submission | Pre-submission meeting | N/A | - |
2 | Submission | Submitted information/data & application fees | - | 30 |
Notification of outcome of preliminary assessment | 30 | |||
3 | First round of Evaluation | Round 1 Evaluation | 100 | 255 |
4 | First round of request for information from sponsor | Response to first s32JA letter from applicant | 30** | |
5 | Second round of Evaluation | Round 2 evaluation | 20 | |
5a | Second round of request for information from sponsor | Response to second s32JA letter from applicant | 30** | |
5b | Third round of Evaluation | Round 3 evaluation | 20 | |
6 | Expert advisory review | Consult the Advisory Committee on Biologicals, if required | 40-60 | |
7 | Decision | Decision | 20 | |
- | Total evaluation timeframe | 200-220 | - | |
8 | Post-decision | ARTG entry and other administrative processes | 20 |
* Timeframes are stated in working days.
** These times represent typical timeframes given to you to respond to requests for information, but may be much longer.
Where a request for further information is made the evaluation is stopped and the period it takes for you to respond is not calculated in the evaluation timeframe.
In some circumstances, we may also stop the clock by mutual agreement with you and restart when the issue has been resolved. For example, when the evaluation has been complete but GMP certification of a manufacturing site has not been granted.
Phase 1: Pre-submission
Phase 2: Submission
Phase 3: First round of evaluation
Phase 4: First round of request for information from sponsor
Phase 5: Second round of evaluation
Phase 5a: Second round of consolidated request for information from sponsor
Phase 5b: Third round of evaluation
Phase 6: Expert advisory review
Phase 7: Decision
Phase 8: Post decision
Version | Description of change | Author | Effective date |
---|---|---|---|
V1.0 | Original publication incorporating new legislative changes and information previously published on the TGA website. | Biological Science Section Regulatory Guidance Team | July 2018 |
V1.1 | Minor updates to reflect CTA name change | Biological Science Section | November 2020 |